Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

Multiple Sclerosis Journal

Volumn 17, Issue 5, 2011, Pages 578-593

  Cook, S ^a   Vermersch, P ^b   Comi, G ^c   Giovannoni, G ^d   Rammohan, K ^e   Rieckmann, P ^f   Sørensen, P Soelberg ^g   Hamlett, A ^h   Miret, M ^h   Weiner, J ^h   Viglietta, V ^h   Musch, B ^h   Greenberg, S J ^h  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIV LILLE   (France)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h MERCK SERONO S A   (Switzerland)

Author keywords

Cladribine tablets; Disease modifying therapy; Lymphopenia; Multiple sclerosis; Randomized controlled trial; Safety; Short course therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLADRIBINE; CREATININE; HEMOGLOBIN; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

ACNE; ACUTE HEART INFARCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BODY TEMPERATURE; CARDIOPULMONARY ARREST; CHORIOCARCINOMA; CONJUNCTIVITIS; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPNEA; DYSURIA; ECTOPIC PREGNANCY; ELECTROCARDIOGRAM; EROSIVE GASTRITIS; FEVER; FLATULENCE; GAIT DISORDER; GASTRITIS; GASTROINTESTINAL SYMPTOM; GENITAL HERPES; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HERPES ZOSTER OTICUS; HOT FLUSH; HUMAN; HYPERTHERMIA; HYPESTHESIA; INCIDENCE; INFECTION; INFESTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MELANOMA; METRORRHAGIA; MIGRAINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUROLOGIC EXAMINATION; NEUTROPHIL COUNT; OVARY CARCINOMA; PAIN; PANCREAS CARCINOMA; PARESTHESIA; PERIODONTITIS; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRECANCER; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SKIN ALLERGY; SKIN TOXICITY; SOMNOLENCE; SPONTANEOUS ABORTION; SYNCOPE; TABLET; THROMBOCYTE COUNT; TINNITUS; TONSILLITIS; TOOTH ABSCESS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX CARCINOMA IN SITU; UTERUS MYOMA; VAGINITIS; VERTIGO; VIRUS INFECTION; VITAL SIGN; VULVOVAGINAL DISEASE; XEROSTOMIA; ADULT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; EUROPE; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; CLADRIBINE; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; EUROPE; HERPES ZOSTER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPENIA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPLASMS; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 80053448175     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510391344     Document Type: Article

References (24)

1. Leist TP and Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23: 2667-2676. (Pubitemid 350146405)
2. Cohen BA. Evolving views of MS pathogenesis. Int J MS Care 2007; 9: 4-10.
3. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R and Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996; 93: 1716-1720. (Pubitemid 26075191)
4. Rice GP, Filippi M and Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-1155. (Pubitemid 30151860)
5. Romine JS, Sipe JC, Koziol JA, Zyroff J and Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44. (Pubitemid 29047108)
6. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J and Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13. (Pubitemid 24199417)
7. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426.
8. International Agency for Research on Cancer (IARC). Statistical methods in cancer research volume 2: The design and analysis of cohort studies, 82nd edn. Lyon, France: International Agency for Research on Cancer (IARC) Scientific Publications, 1987, pp.49-65.
9. International Agency for Research on Cancer (IARC). Cancer Incidence in Five Continents, Vol IX, No.160.http://www-dep.iarc.fr/CI5-IX-frame.htm (accessed 9June 2009).
10. GLOBOCAN. The GLOBOCAN 2002 database. http://www-dep.iarc.fr/globocan/ database.htm (accessed April2009).
11. ACOG. American College of Obstetricians and Gynecologists Practice Bulletin No.99: Management of Abnormal Cervical Cytology and Histology. Obstet Gynecol 2008; 112: 1419-1444.
12. US Food and Drug Administration. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 29 July 2009. http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064993.htm (accessed 2 September 2010).
13. Chapman RS, Cross KW and Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21: 2541-2547. (Pubitemid 36561347)
14. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K and Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191: 2002-2007.
15. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ and Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349. (Pubitemid 350060129)
16. Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplege A, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33: 62-69. (Pubitemid 32554504)
17. Fleming DM, Cross KW, Cobb WA and Chapman RS. Gender difference in the incidence of shingles. Epidemiol Infect 2004; 132: 1-5. (Pubitemid 38240065)
18. Opstelten W, van Essen GA, Schellevis F, Verheij TJ and Moons KG. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16: 692-695. (Pubitemid 44190173)
19. Gnann JW and Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: 340-346.
20. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL and Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48: S2-S7.
21. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997; 90: 967-973. (Pubitemid 27510139)
22. Viglietta V, Greenberg S, Mikol D, Weiner J, Alteri E, Chang P, et al. Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis. (Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis, Dusseldorf, Germany, 9-12 September 2009). (P439). Mult Scler 2009; 15: S126-S127.
23. Miret M, Perez-Gutthann S, Gutierrez L, Viglietta V, Musch B and Greenberg S. Evaluation of the long-term safety of cladribine tablets: design of a prospective observational 8-year safety registry. (Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis, Dusseldorf, Germany, 9-12 September 2009). (P788). Mult Scler 2009; 15: S239.
24. Pearl R. Factors in human fertility and their statistical evaluation. Lancet 1933; 222: 607-611.